BioMarin Pharma (BMRN) Tops Q1 EPS by 39c, Revs Beat; Trims FY Rev Outlook
Get Alerts BMRN Hot Sheet
Price: $91.20 --0%
Revenue Growth %: +8.8%
Financial Fact:
Weighted average common shares outstanding, diluted: 167.71M
Today's EPS Names:
UXIN, TOWN, NRIM, More
Revenue Growth %: +8.8%
Financial Fact:
Weighted average common shares outstanding, diluted: 167.71M
Today's EPS Names:
UXIN, TOWN, NRIM, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $0.44, $0.39 better than the analyst estimate of $0.05. Revenue for the quarter came in at $502.1 million versus the consensus estimate of $468.77 million.
GUIDANCE:
BioMarin Pharma sees FY2020 revenue of $1.85-1.95 billion, versus prior of $1.95-$2.05 billion and the consensus of $1.97 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $85 at Scotiabank
- Newmont (NEM) Tops Q1 EPS by 19c
- MarineMax (HZO) Misses Q2 EPS by 48c, provides guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!